Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

University of Barcelona, Barcelona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:5City/State/Province:Barcelona
Treatments:Biologic therapyHospital:University of Barcelona
Drugs:Journal:Link
Date:Jun 2013

Description:

Patients:
This phase 2 study involved 36 hepatocellular carcinoma patients who had been previously treated with sorafenib. The median patient age was 61 years and 89% were male.

Treatment:
Patients were treated with the biologic therapy agent called regorafenib, which is a kinase inhibitor that interferes with cancer cell growth.

Toxicities:
There were study-related deaths due to cerebral hemorrhage and bleeding reported for this study. Grade 3-4 fatigue, hand-foot skin reaction, and diarrhea were also reported.

Results:
The median overall survival was 13.8 months.

Support:
This study was funded by Bayer HealthCare Pharmaceuticals.

Correspondence: Dr. Jordi Bruix; email: [email protected]



Back